摘要
芪蛭通络胶囊是由26味中药材组成,用于中风恢复期后遗症的辅助治疗。该复方组成复杂,但其化学成分以及药效物质基础研究目前未见报道。该研究拟采用超高效液相色谱-四极杆-静电场轨道肼高分辨质谱联用(UPLC-Q-Orbitrap HRMS)技术对芪蛭通络胶囊的化学成分进行快速鉴定。采用Waters Acquity UHPLC HSS T3 column柱进行色谱分离,以乙腈-水溶液为流动相进行梯度洗脱,以电喷雾质谱检测,正负离子模式下采集数据,根据化合物的精确相对分子质量、质谱裂解规律等信息结合对照品比对和文献报道的质谱数据进行化合物解析,并对各成分的来源进行归属,共鉴定出119个化合物,包括黄酮类22个、皂苷类12个、丹酚酸类10个、丁基苯酞类5个、蒽醌类4个、单萜苷类4个、咖啡酰基奎尼酸类2个、香豆素类2个、生物碱类2个、二苯乙烯类1个。此外,所鉴定的化合物还包括多种氨基酸、有机酸等中药材共性成分。该研究首次对芪蛭通络胶囊的化学成分进行了快速的表征,该结果为其进一步的药效物质基础研究和质量评价奠定了基础。
Qizhi Tongluo Capsules, which is composed of 26 herbal drugs, is mainly used as the assistant therapy for apoplexy sequelae. The chemical composition of Qizhi Tongluo Capsules was complex,but its chemical constituents and the pharmacodynamic material basis remain unreported. The ultrahigh performance liquid chromatography coupled with hybrid quadrupole-orbitrap mass spectrometry(UPLC-Q-Orbitrap HRMS) was applied to recognize the chemical constituents of Qizhi Tongluo Capsules. The analysis was performed on a Waters Acquity UHPLC HSS T3 column with acetonitrile-water as the mobile phase for gradient elution. Heated electrospray ionization(HESI) in both positive and negative ion modes was adopted to collect the data. The chemical constituents were identified and confirmed by analyzing the accurate molecular weight, the mass fragmentation pattern, and comparing with the mass data from the reference substances and literature. A total of 119 components were identified, including 22 flavones, 12 saponins, 10 salvianolic acids, 5 butylphthalides, 4 anthraquinones, 4 monoterpenoid glycosides, 2 caffeoyl-quinic acids, 2 coumarins, 2 alkaloids, and 1 stilbene, as well as the common constituents in the herb, such as amino acids and organic acids. The chemical constituents of Qizhi Tongluo Capsules were characterized rapidly for the first time in this study, laying a foundation for the further analysis of active compounds and quality control.
作者
李蓉蓉
游蓉丽
秦雪梅
李震宇
LI Rong-rong;YOU Rong-li;QIN Xue-mei;LI Zhen-yu(Modern Research Center for Traditional Chinese Medicine,Shanxi University,Taiyuan 030006,China;Beijing Zhendong Guangming Pharmaceutical Research Institute Co.,Ltd.,Beijing 100085,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第20期4918-4928,共11页
China Journal of Chinese Materia Medica
基金
山西省重点实验室项目(201605D111004)。
作者简介
通信作者:李震宇,教授,硕士生导师,研究方向为中药质量控制及活性成分研究,E-mail:lizhenyu@sxu.edu.cn;李蓉蓉,硕士研究生,E-mail:lirrsxu@163.com。
